Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid as adjunctive therapy for clozapine-resistant schizophrenia
IRCT20250216064739N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ursodeoxycholic acid in schizophrenia, sponsored by Zahedan University of Medical Sciences. Started Feb 2025; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20250216064739N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250216064739N1.